Skip to main content

Ovarian Cancer

Phase 1 Trial of Ribociclib (LEE-011) with Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer

ARIEL4 Results of Rucaparib versus Chemotherapy in Patients with Advanced, Relapsed Ovarian Cancer and a Deleterious BRCA Mutation

Progression-Free Survival Benefit from Maintenance Olaparib in Patients with Platinum-Sensitive Relapsed Ovarian Cancer by BRCA and Other Homologous Recombination Repair Gene Mutation Status (ORZORA Trial)

Olaparib Treatment in Patients with Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status: Secondary Safety Results from the Phase 2 LIGHT Study

5-Year Follow-Up of the SOLO1/GOG 3004 Trial of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation

Subgroup Analysis of the ARIEL4 Study of the Effect of Platinum Sensitivity on Efficacy of Rucaparib versus Chemotherapy for BRCA-Mutated, Advanced, Relapsed Ovarian Carcinoma

Analysis of the Phase 3 PAOLA-1/ENGOT-ov25 Trial by Disease Stage in Patients with Homologous Recombination Deficiency–Positive Newly Diagnosed Advanced Ovarian Cancer Receiving Bevacizumab with Olaparib/Placebo Maintenance

EFFORT Study of Adavosertib with or without Olaparib in Women with PARP-Resistant Ovarian Cancer

Final Overall Survival Results from the LIGHT Study of Olaparib Treatment in Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status

Phase 3b OPINION Primary Analysis of Olaparib Maintenance Monotherapy for Nongermline BRCA1/2-Mutated Platinum-Sensitive Relapsed Ovarian Cancer

1
2
3
4
5
6

Page 3 of 13
Results 21 - 30 of 122